Cash-rich biotech, still waiting on approvals
- Roivant has no direct product sales after selling Dermavant to Organon in October 2024.
- Its main near-term test is the FDA decision for brepocitinib in dermatomyositis by late September 2026.
- IMVT-1402 looks more credible after open-label Phase 2 rheumatoid arthritis data, but it still needs bigger trials.
- Cash was $4.3 billion at March 31, 2026, before the expected $950 million Moderna settlement payment in July 2026.
- The bear case is simple: a high-priced biotech with no approved in-house product can lose value fast if trials fail.
Big cash, big trial risk
Roivant is stronger than it was a year ago. Brepocitinib has an FDA review date in dermatomyositis, and the same drug now has more shots on goal in non-infectious uveitis, cutaneous sarcoidosis, and lichen planopilaris. The FDA also gave brepocitinib Breakthrough Therapy Designation in cutaneous sarcoidosis, which means the agency sees early evidence that it could matter in a serious disease.
The most important new data point is IMVT-1402. In an open-label Phase 2 rheumatoid arthritis study, Roivant reported ACR20, ACR50, and ACR70 response rates of 72.7%, 54.5%, and 35.8%. ACR is a score doctors use to measure arthritis improvement. This was in a hard-to-treat group, so the result helps the bull case.
The balance sheet gives Roivant time. The company reported $4.3 billion of cash, cash equivalents, and marketable securities at March 31, 2026. It also expects a $950 million fixed payment from the Moderna settlement in July 2026, with another $1.3 billion possible if a legal appeal is resolved in its favor.
The catch is that Roivant is still a clinical-stage biotech. It sold Dermavant, so it no longer has an approved product that it sells itself. The current stock price leaves little room for bad news if brepocitinib is rejected, IMVT-1402 stumbles in later trials, or the Moderna legal upside does not arrive.
A factory for Vants
Roivant does not look like a normal drug company. It creates separate subsidiaries called Vants. Each Vant focuses on one medicine, one technology, or a narrow group of programs. Roivant keeps ownership, helps fund the work, and decides where to put capital.
After the October 2024 Dermavant sale, Roivant no longer depends on direct product revenue. Future money may come from approvals, launch sales, license fees, milestones, royalties, and partner payments. It may also collect economics tied to VTAMA, which Organon now owns and sells.
This model can work well when Roivant buys or licenses an overlooked drug and moves it through trials faster than larger companies would. It can also create extra complexity. Vant teams may have their own incentives, and investors have to track several separate bets instead of one clean business line.
For now, research spending is the core activity. The company said research and development will stay central to the business model and may increase as trials move forward.
The assets that matter
Brepocitinib
This TYK2 and JAK1 inhibitor is under FDA review for dermatomyositis, with a target action date in the third quarter of 2026. It is also in late-stage work for non-infectious uveitis, cutaneous sarcoidosis, and lichen planopilaris.
IMVT-1402
IMVT-1402 is a fully human antibody that targets FcRn, a pathway tied to several autoimmune diseases. The rheumatoid arthritis Phase 2 data raised confidence, but the key proof still has to come from larger and more controlled studies.
Mosliciguat
Mosliciguat is an inhaled sGC activator for pulmonary hypertension linked to interstitial lung disease. Phase 2 PHocus data expected in the second half of 2026 will decide whether this becomes a larger Roivant program.
VTAMA economics
Roivant sold Dermavant to Organon, but kept rights to possible future milestones and royalties tied to VTAMA. This is not a core operating business anymore, but it can still bring in cash if sales and regulatory goals are met.
Genevant LNP platform
Genevant owns lipid nanoparticle technology, often called LNP, used to deliver genetic medicines. Its Moderna settlement adds cash now, while the extra $1.3 billion depends on a favorable appeal outcome.
Vants, not sales segments
Roivant does not report normal revenue segments. The mix below uses the disclosed ownership stakes in key Vants from the company context and 10-K framing, normalized across Immunovant, Priovant, and Pulmovant, so it is a pipeline exposure view, not a revenue view.
What could break the story
Brepocitinib rejection
High impact · Medium oddsBrepocitinib is the closest asset to approval. A negative FDA decision in dermatomyositis would hurt the near-term launch story and make the rest of the brepocitinib pipeline feel riskier. Even a delay could matter because investors are waiting for a commercial proof point.
IMVT-1402 trial fade
High impact · Medium oddsThe rheumatoid arthritis data came from an open-label Phase 2 study, where doctors and patients know the treatment being used. That can make early results look better than later controlled trials. If response rates, safety, or dosing look worse in bigger trials, Roivant's largest immunology bet could lose value.
No product revenue cushion
High impact · High oddsRoivant sold Dermavant, so it has no commercial-stage product of its own. That means the company can have a large cash balance and still depend on future approvals. If launches are delayed, cash buys time but does not prove the business model.
HanAll dispute over batoclimab
Medium impact · Medium oddsBatoclimab failed two Phase 3 thyroid eye disease studies, and Immunovant stopped development across indications. HanAll licensed the anti-FcRn assets, and it may disagree with that decision. A dispute could consume cash, time, and management focus.
Vant model friction
Medium impact · Medium oddsThe Vant model can move fast, but it can also create overlapping costs and hard-to-read incentives. Each unit has its own focus, while Roivant has to allocate capital across the whole group. Poor capital choices could dilute the benefit of the large cash balance.
Moderna appeal uncertainty
Medium impact · Medium oddsThe fixed Moderna payment is expected in July 2026, but the extra $1.3 billion is contingent. If the appeal does not go Genevant and Arbutus's way, investors should not count that full amount as cash. This matters because the market may give Roivant credit for legal upside before it is final.
In one breath
Does Roivant have any approved products?
Roivant no longer sells an approved product itself after the Dermavant sale to Organon. It still has possible milestone and royalty economics tied to VTAMA.
What is the next big Roivant catalyst?
The biggest near-term catalyst is the FDA decision on brepocitinib in dermatomyositis, expected by late September 2026. Investors are also watching mosliciguat Phase 2 data and brepocitinib Phase 3 data in non-infectious uveitis in the second half of 2026.
Why is IMVT-1402 important?
IMVT-1402 is Roivant's next major anti-FcRn bet after batoclimab was stopped. It could apply to several autoimmune diseases, but it still needs larger trials to confirm the early rheumatoid arthritis signal.
Why does valuation matter for ROIV?
Roivant has a lot of cash, but investors are also paying for future approvals and pipeline success. If a major trial or FDA decision disappoints, the stock can fall even if the balance sheet remains strong.